Natera @ ASCO

ASCO 2024

Feasibility of Tumor-Informed Circulating Tumor DNA (ctDNA) for Molecular Residual Disease (MRD) Assessment in Pediatric Patients with Solid

Read More

Personalized circulating tumor (ct)DNA for monitoring disease status in head and neck squamous cell carcinoma

Read More

Longitudinal Analysis of Circulating Tumor DNA in Localized and Metastatic Urothelial Cancer

Read More

Association Between Circulating Tumor DNA and Recurrence-Free Survival in Patients with Resected Stage III Melanoma

Read More

A targeted panel of actionable high risk hereditary cancer predisposition genes can identify patients with pathogenic/likely pathogenic vari

Read More

Longitudinal Evaluation of Circulating Tumor DNA (ctDNA) as a Prognostic Biomarker to Detect Minimal Residual Disease (MRD) in Testicular Ca

Read More

Trial in Progress: Randomized phase III study comparing suspension or continuation of PD-1 Pathway Blockade for patients with advanced non-s

Read More

Abstract # 518: ctDNA monitoring for breast cancer at high risk of recurrence: Interim analysis of JCOG1204A1

Read More

Abstract 3598: Association of circulating DNA with recurrence in CRS-HIPEC patients with colorectal and appendiceal peritoneal carcinomatosi

Read More

Predicting response to neoadjuvant therapy (NAT) in patients (pts) with early-stage breast cancer (BC) using circulating tumor DNA (ctDNA) t

Read More

Longitudinal circulating tumor DNA (ctDNA) analysis during treatment (Tx) of locally advanced resectable (LAR) gastric or gastroesophageal j

Read More

Genomic alterations in early-onset versus average-onset stage IV colorectal cancer

Read More

Impact of circulating tumor DNA (ctDNA) surveillance on clinical care for patients with stage I-III breast cancer: Findings from a multi-ins

Read More

ASCO 2023

almost 2 years ago

ASCO 2023 - Circulating Tumor DNA and Association with CAR-T Cell Therapy Response in Gastric and Pancreatic Cancer Patients

Read More

almost 2 years ago

ASCO 2023 - Utilization of Circulating Tumor DNA Analysis to Detect Minimal Residual Disease Post-surgery and Disease Progression in Metasta

Read More

almost 2 years ago

ASCO 2023 - Utility of circulating tumor DNA (ctDNA) as a predictive biomarker for disease monitoring in patients (pts) with cholangiocarcin

Read More

almost 2 years ago

ASCO 2023 - Circulating tumor DNA dynamics as an early predictor of recurrence in patients with radically resected colorectal cancer: Updat

Read More

almost 2 years ago

ASCO 2023 - Circulating Tumor Dna As A Marker Of Recurrence Risk In Locoregional Esophagogastric Cancers With Pathologic Complete Response

Read More

almost 2 years ago

ASCO 2023 - Longitudinal circulating tumor DNA monitoring for detection of molecular residual disease in patients with surgically resected

Read More

almost 2 years ago

ASCO 2023 - Longitudinal circulating tumor DNA monitoring in patients with esophageal squamous cell carcinoma

Read More

Loading More...